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Abstract 
Cancer is one of the leading causes of morbidity and mortality around the world. Despite some success, traditional anticancer 
drugs developed to reduce tumor growth face important limitations primarily due to undesirable bone marrow and cardiovascular 
toxicity. Many drugs fail in clinical development after showing promise in preclinical trials, suggesting that the available in vitro and 
animal models are poor predictors of drug efficacy and toxicity in humans. Thus, novel models that more accurately mimic the 
biology of human organs are necessary for high-throughput drug screening. Three-dimensional (3D) microphysiological systems 
can utilize induced pluripotent stem cell technology, tissue engineering, and microfabrication techniques to develop tissue models 
of human tumors, cardiac muscle, and bone marrow on the order of 1 mm3 in size. A functional network of human capillaries and 
microvessels to overcome diffusion limitations in nutrient delivery and waste removal can also nourish the 3D microphysiological 
tissues. Importantly, the 3D microphysiological tissues are grown on optically clear platforms that offer non-invasive and non-
destructive image acquisition with subcellular resolution in real time. Such systems offer a new paradigm for high-throughput drug 
screening and will significantly improve the efficiency of identifying new drugs for cancer treatment that minimize cardiac and bone 
marrow toxicity. 
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Introduction 
Current drug screening methods usually rely on two-
dimensional (2D) systems or animal models for assessment 
of toxicity, pharmacokinetics, pharmacodynamics, and 
organ system effects. While 2D cell culture lacks the inher-
ent complexity of in vivo tissues in three-dimensional (3D) 
arrangements, the intrinsically different biology of animal 
models fails to capture the human-specific response to 
drugs. To more accurately simulate the in vivo physiologic 
human response to pharmacologic challenge, it is highly 
desirable to replicate the complex 3D arrangements of 
human cells, including, preferably, multiple organ systems 
and a vascular supply. The vasculature not only provides 
the necessary convective transport of nutrients and waste in 
3D culture, but it also couples and integrates the response of 
the multiple organ systems. Additionally, most drugs are 
delivered to the target tissue through the microcirculation, 
and thus incorporation of a vasculature best mimics in vivo 
drug delivery. 
Drug delivery to a target tissue depends on the function 
of other organs. To achieve the desired effect of a selected 
drug on a given tissue, the presence of multiple organ sys-
tems may be required. In chemotherapy, for example, the 
gastrointestinal, circulatory, and urinary systems each con-
tribute to determine the pharmacokinetics of a given drug. 
If a drug possesses useful activity, it will be further studied 
for possible adverse effects on major organs. While adverse 
effects on the multiple organ systems throughout the body 
are important, current anticancer therapies are mostly lim-
ited by their undesirable side effects on the immune system, 
the cardiovascular system, and the liver. First-pass drug 
metabolism in the liver prior to entry into the vascular 
system can markedly influence the toxicity of a wide range 
of drugs. However, in cancer treatment it is well established 
that the majority of antiproliferative agents used in trad-
itional chemotherapy can cause myelosuppression in a 
dose-dependent manner (e.g. alkylating agents, pyrimidine 
analogs, anthracyclines, methotrexate, etc.).1 The use of 
hematopoietic growth factors has significantly improved 
the primary acute myelosuppression observed during 
anticancer treatments;2 however, in some patients these 
growth factors can also mask development of a latent resi-
dual bone marrow injury manifested by a decrease in hem-
atopoietic stem cell (HSC) reserves and an impairment in 
HSC self-renewal.3 Regarding the cardiovascular system, 
systemic anticancer therapy can lead to hypertension, 
thromboembolic events, left ventricular dysfunction, myo-
cardial ischemia, arrhythmias, and pericarditis.4–6 In this 
regard, two types of cardiotoxicity have been well estab-
lished according to the type of damage in the cardiomyo-
cyte: type I-induced cardiotoxicity (e.g. induced by 
anthracycline), which is dose dependent and associated 
with myocyte death; and, type II-related cardiotoxicity 
(e.g. induced by trastuzumab), which is less predictably 
associated with dose, and typically correlated with revers-
ible myocardial dysfunction rather than histological 
changes or myocyte death. However, with the increase of 
a wide range of new anticancer agents used in molecularly 
targeted therapy, an unintended cardiotoxicity, recently 
classified as ‘off-target,’ has arisen from many of these com-
pounds. Off-target cardiotoxicity results from the inherent 
challenge of targeting molecules such as specific kinase 
inhibitors. Although inhibition of specific kinases is effect-
ive in treatment of some cancers, kinase inhibitors are a 
relatively ubiquitous class of molecules that can uninten-
tionally affect non-cancerous tissues, especially cardiac 
tissue. This new class of drugs has increased the risk and 
need for assessment of chemotherapy-associated 
cardiotoxicity.1–3,6 
To address the need for improved preclinical drug tox-
icity models, we are developing a system for high-through-
put screening of both drug efficacy and organ-specific 
toxicity. Our system features 3D tissues made entirely of 
human cells. The tissues are connected and perfused by 
human microvessels. Initial designs incorporate tumor, car-
diac, and bone marrow tissue modules that allow assess-
ment of anticancer drug efficacy as well as potential side 
effects. 
Pharmacology 
Once a new drug target has been identified, a sequence of 
studies is initiated to characterize the dose–response rela-
tionship prior to clinical trials. A variety of assays at the 
molecular, cellular, organ, and systemic levels are needed 
to define the pharmacokinetics and pharmacodynamics of 
the drug. Pharmacokinetics is the study of changes in drug 
concentration with time due to absorption, distribution, 
metabolism, and elimination of the drug. In contrast, 
pharmacodynamics is the study of the drug concentra-
tion-dependent tissue or cell response. The target tissue is 
normally represented by a dose–response curve. The EC50 
of a drug is an index of its sensitivity or potency and refers 
to the concentration required to produce 50% of that drug’s 
maximal effect (e.g. tumor reduction or antiproliferative 
effect in response to an anticancer agent). The maximal effi-
cacy of a drug represents the upper limit of the dose– 
response relation on the response axis. 
In cancer treatment, the same total drug dose can be 
delivered over different lengths of time (i.e. different dose 
intensities), which can impact the effect of the drug on other 
organ systems. The goal of chemotherapeutics is to achieve 
a desired effect with minimal adverse side effects; therefore, 
when designing a microphysiological system for drug 
screening, it is important to recognize that many anticancer 
drugs are limited by their adverse effect on a number of 
non-cancerous tissues throughout the body. As further 
introduced below, the proposed system recognizes that 
the response of cells and tissues to a pharmacologic chal-
lenge is greatly influenced by the microenvironment. 
Table 1 categorizes a wide range of important microenvir-
onmental factors that are present in the 3D architecture of 
the tissue that influence tissue response to a drug. 
Drug behavior in 2D versus 3D systems 
Differences in cell morphology, differentiation, prolifer-
ation, viability, response to stimuli, metabolism, and 
gene/protein expression are observed when cells, previ-
ously cultured in 2D, are moved to a 3D environment.7 
This is not surprising considering that human organs, 
with few exceptions, need 3D structure to develop their 
associated functions.8,9 A well-known example of the neces-
sity of 3D models for testing toxicity of novel therapeutics is 
the culture of hepatocytes, which behave quite differently in 
2D versus 3D cultures.10 
In cancer research, the idea of mimicking 3D tissue func-
tion in vitro is not new. Tumor spheroids, for example, were 
presented nearly four decades ago.11 However, given the 
fact that 2D systems are relatively easy to culture, provide 
simple assessment of cell function (e.g. protein expression), 
and are lower in cost, the adoption of 3D systems has been 
relatively slow. Nevertheless, recent studies have enhanced 
our understanding of the necessity for testing the efficacy of 
anticancer drugs in 3D systems. For example, among other 
differences, tumor cells in 3D adopt a different morphology 
than in 2D,12 have different cell surface receptor expression 
and proliferation;13differentially regulate genes responsible 
for angiogenesis, cell migration, and invasion;14–16 and have 
different extracellular matrix (ECM) synthesis.17 
Importantly, tumor cells in 3D also show differences in 
anticancer drug sensitivity. Studies have shown that cultur-
ing cancer cells in 3D can shift their dose–response, some-
times to the point where they become functionally resistant 
to the drug. For instance, culturing of cancer cells in a 3D 
system can lead to an increase of 20-fold or more in the EC50 
compared with 2D culture when cancer cells are exposed to 
doxorubicin.18 Moreover, recent studies suggest that 3D 
models, unlike 2D culture, more accurately predict 
acquired drug resistance.19 Drugs that target molecular 
pathways have shown differences in activation or inhibition 
depending on the 3D architecture of the local 
Table 1 Drug testing of tumor cells cultured in 3D 
Tumor cell line Outcome of drug treatment Refs. 
I. 2D vs. 3D culture systems – Examples of observed differences in drug response 
Ia. Cancer cells cultured in 3D are more resistant to anticancer drugs compared with 2D 
HepG2 human liver hepatocellular carcinoma Responses of cells to cisplatin, 5-fluorouracil and Li et al.98 
cells doxorubicin (anticancer drugs) showed higher 
EC50 values in 3D multicellular spheroids compared 
with 2D monolayer. The 3D model conferred dif-
ferentiated phenotypes including increased cell– 
cell adhesion, G1 phase cell cycle arrest, and 
enhanced cellular resistance to apoptosis 
SA87 (brain metastases), NCI-H460 and Responses of cells to increasing concentrations of David et al.99 
H460M (lung) lines from primary tumors and anticancer drugs such as doxorubicin and 5-
metastases fluorouracil showed that 3D models conferred 
more resistance to the drugs than the usual 
monolayer culture system. The anticancer drugs 
were efficient after 24 h of treatment in the mono-
layer cultures, whereas they were significantly 
efficient after only 1 week of incubation in the 3D 
systems 
TE2 and TTn human esophageal squamous Responses of cells to anticancer drugs such as cis- Fujiwaraet al.100 
carcinoma lines platin and doxorubicin showed higher EC50 values 
in 3D cultured cells compared with 2D demon-
strating a higher increase of drug resistance in 3D 
models 
MCF-7 breast cancer cells The antiproliferative effect of different anticancer Horning et al.18 
agents including doxorubicin, paclitaxel, and 
tamoxifen in 3D models was significantly lower 
than in 2D monolayer by a 12- to 23-fold difference 
in their EC50 values. The greater synthesis of col-
lagen in 3D suggested that the ECM can act as a 
barrier to drug diffusion 
Ib. Cancer cells cultured in 3D makes them resistant or desensitizes the cancer depending on the cell and/or drug type 
C4-2B bone metastatic prostate cancer cells Responses of cells to camptothecin, docetaxel, and Gurski et al.101 
rapamycin (anticancer drugs), alone and in com-
bination, differed between the 3D and 2D mono-
layer systems 
HT29, SW620, SW1116 (colon) UM-SCC-22B Responses of cells to anticancer drugs such as cis- Padron et al.102 
(head and neck), and A2780 (ovary) solid platin and miltefosine showed that multilayers are 
tumor cell lines more resistant to the drugs than the corresponding 
monolayers. However, there are substantial differ-
ences between the drugs depending on culture 
conditions 
A549 and H358 lung cancer cell lines Potency and efficacy from a set of 10 anticancer drugs Nirmalanandhan et al.103 
including paclitaxel, doxorubicin, vinorelbine, 
gemcitabine, or cisplatin showed significant dif-
ferences when tested in 3D cultured cells compar-
ing with traditional 2D cultures. The activity of these 
drugs varied with individual drugs and the cell line 
used for testing 
Ic. Anticancer drugs demonstrate different effectiveness in 3D compared with 2D. ECM involvement and selective pathway interaction differences 
U87 (glioblastoma), PC3 (prostate), T47D 
(breast), and HCT116 (colon) human cancer 
cell lines 
AU565, SKBR3, HCC1569, and BT549 HER2-
amplified breast cancer cell lines 
Cells exposed to both PX-866 and wortmannin 
phosphatidylinositol-3-kinase inhibitors sup-
pressed 3D spheroid growth at low concentrations, 
unlike in 2D monolayer which failed to inhibit cell 
growth even in higher concentrations 
Drug response to trastuzumab and pertuzumab (two 
anti-HER2 agents) was highly dependent on 
whether the cells were cultured in 2D monolayer or 
3D laminin-rich ECM gels. Inhibition of b1 integrin 
significantly increased the sensitivity of the HER2-
amplified breast cancer cell lines to the drugs when 
they grow in a 3D environment. 
Howes et al.21 
Weigelt et al.22 
(continued) 
Table 1 Continued 
Tumor cell line Outcome of drug treatment Refs. 
Ishikawa, RL95-2, KLE endometrial cancer cell 3D multicellular cultures exposed to the anticancer 
agents such as doxorubicin and cisplatin exhib-
ited greater resistance to the drugs than 2D 
monolayers. Their effects on the intracellular 
mediators were not similar in 3D and 2D cultures, 
including selective paradoxical stimulatory effects 
on VEGF secretion. Differences were also 
dependent on cancer cell lines. 
Chitcholtan et al.20 
II. ECM environment – Examples of observed differences in drug response 
IIa. The ECM that surrounds the tumor cells impacts pharmacodynamics 
HT1080 human fibrosarcoma cells 
H1299, PC3, HCT116 colon cancer cells 
MIA PaCa-2, PANC-1, and Capan-1 pancreatic 
cell lines 
The anti-invasive effect of doxorubicin observed in 
conventional 2D culture was completely abolished 
in a 3D environment. The 3D collagen type I matrix 
inhibited the antimigratory effect of the drug 
3D cultured cells treated with 5-fluorouracil resulted 
in p53 stabilization and angiogenesis inhibition by 
increasing the production of arresten, a collagen 
IV-derived fragment that possesses antiangiogenic 
activity. The presence of ECM contributed to the 
antiangiogenic effect of an anticancer drug 
Cancer cell lines adhering to ECM proteins (collagen I, 
collagen IV, fibronectin, and laminin) showed 
decreased cytotoxicity of anticancer drugs such as 
doxorubicin, cisplatin, and 5-fluorouracil, but not 
gemcitabine 
Millerot-Serrurot et al.24 
Assadian et al.23 
Miyamoto et al.104 
III. Other cell types in the 3D microenvironment – Examples of observed differences in drug response 
IIIa. Interactions with stromal cells involved in drug sensitivity and development of drug resistance 
T3M4 and PT45-P1 pancreatic carcinoma cell Tumor cell lines cultured in presence of fibroblasts Muerkoster et al.105 
lines and murine pancreatic fibroblasts became much less sensitive toward treatment with 
the anticancer agent etoposide. Fibroblasts con-
tribute to the development of chemoresistance via 
increased secretion of NO and release of IL-1 by the 
tumor cells 
Different human cancer and NIH3T human Fibroblast-derived 3D matrix increased b1-integrin- Serebriiskii et al.106 
fibroblast dependent survival of a subset of human cancer 
cell lines during taxol treatment, while it sensitized 
or minimally influenced survival of other cells 
IIIb. Presence of ECs are necessary for tumor growth and progression, and also influence the optimal or impaired drug delivery to the tumor tissue 
Observation Refs. 
ECs, beside providing the blood supply to the tumor that allow it to grow and progress, are also responsible for Carmelie and Jain25 
carrying therapeutic drugs to reduce it 
Antiangiogenic drugs used as a therapeutic strategy must be examined further in order to find a balance between Goel et al.107 
therapeutic efficacy and excessive vascular regression preventing adequate drug delivery 
The use of vascular disrupting agents can reduce tumor growth and progression by inducing occlusion of the Thorpe108 
tumor vasculature, which in turn leads to tumor necrosis 
IV. Other factors in a 3D complex that might influence drug response 
IVa. Hypoxia and drug transporter expression 
Tumor cell line Outcome of drug treatment Refs. 
MCF7 breast cancer cells 3D cultured spheroids, unlike in 2D monolayer, Doublier et al.19 
showed an increase in the multidrug resistance 
transporter Pgp via activation of hypoxia inducible 
factor (HIF-1) which contributes to increased 
doxorubicin drug resistance 
WiDr colon cancer cells Cells cultured as multilayer have a lower uptake of Peters et al.109 
antifolates, including the anticancer drug metho-
trexate, compared with monolayers. This higher 
resistance may be related to a decrease in the 
reduced folate carrier drug transporter when cells 
are cultured in 3D. 
(continued) 
Table 1 Continued 
Tumor cell line Outcome of drug treatment Refs. 
HT29 human colon cancer cells 3D multicellular layers are necessary to predict Hicks et al.110 
hypoxia-activated anticancer drugs such as tira-
pazamine since their diffusion through the extra-
vascular tumor compartment may limit their activity 
IVb. Vascular shear stress 
Colo205 colon human cancer cells 3D spheroids cultured in flow showed a threefold Agastin et al.111 
increase in resistance to doxorubicin 
compared to monolayer cells cultured under static 
conditions 
V. Example of other organs affected by the need of a 3D complex in response to an optimal drug screening 
Cell line Outcome of drug treatment Refs. 
Primary human hepatocytes (PHH) For testing toxicity of novel therapeutics, the culture of Schyschka et al.10 
hepatocytes needs a 3D complex to retain their 
functions and predict hepatotoxicity, since they 
quickly stop producing drug metabolizing enzymes 
when cultured on a 2D monolayer 
Mammary epithelial cells The cell matrix interactions in 3D are critical to recap- Roskelley et al.9 and 
itulate the structure and function of the mammary Chen et al.112 
gland. Drug sensitivity of mammary epithelial cells 
cultured in 3D and in 2D showed significant 
differences 
microenvironment.20–22 In addition, the composition of the 
ECM can significantly affect the antimigratory effect of 
some drugs.23,24 These examples demonstrate that tumor 
cell biology in 3D culture is significantly different than 
2D, leading to differences in drug efficacy. Although 
in vitro, the results in 3D culture may be more representative 
of the way cancer cells in vivo respond to chemotherapeutic 
treatment. Table 1 summarizes and highlights the role that 
the ECM, stromal cells (e.g. fibroblasts), vasculature, and 
other factors present in the tumor microenvironment can 
play in modulating drug response, sensitivity, and drug 
resistance. 
The drug response differences between 2D and 3D 
models suggest that pathways necessary for survival in a 
3D environment may not be activated in 2D. As a result, 
drug screening performed on 2D monolayers can increase 
the false-positive and false-negative rates of investigational 
compounds. While false-positive results can increase failure 
of drugs in clinical trials, false-negatives discard potentially 
effective drugs. The use of 3D microphysiological systems is 
predicted to reduce the rate of false-positive and false-
negative outcomes, thereby reducing the need for animal 
testing and improving the overall efficiency of drug 
discovery. 
Drug panel and strategy for validation 
Microphysiological systems need to exhibit drug responses 
that parallel those seen in vivo. Our strategy for validating 
tissue responses includes a panel of common drugs 
(Table 2). The panel distinguishes drugs considered to be 
traditional chemotherapy from those that can be classified 
as molecularly targeted therapy and considers known and 
poorly understood cardiac muscle and bone marrow tox-
icity. The panel also recognizes other important observed 
effects in order to validate, predict, and better understand 
the response, toxicity, and effectiveness of the drug. 
Design of in vitro microphysiological systems 
To address the numerous potential side effects of anticancer 
drugs on multiple tissues and organ systems, robust in vitro 
microphysiological systems have been developed for pre-
clinical high-throughput screening of candidate drugs. 
These systems need to mimic critical functions and anatom-
ical features of in vivo tissues to generate an appropriate 
response to a pharmacologic challenge. It is important to 
note that because of the complex nature of in vivo tissues, it 
may be impractical and unnecessary to mimic all the func-
tions and architecture of in vivo tissues. In this view, an 
optimal level of anatomical complexity that has bearing 
on drug distribution and response of in vivo tissues needs 
to be reflected in the microphysiological systems. 
Each specific organ system presents unique challenges to 
correlate in vitro performance with in vivo physiology and 
pathology associated with anticancer drugs. The following 
sections discuss the critical features of major organ systems 
and their anticancer drug-related behavior. Methods for 
mimicking these features in vitro within the proposed 
microphysiological platform are also presented. 
Vascular system 
One of the most prominent features of all human tissues is 
vasculature, which provides a convective mode of transport 
for nourishment and waste removal. The Vascular transport 
Table 2 Example drug panel – Strategy for validation. 
Target Approved drug Outcome of drug treatment 
I. Physiologic validation of cardiac muscle and microvasculature function 
Ia. Cardiac muscle validation. Example of representative drugs for cardiac validation 
L-type Ca2þ channel Verapamil; L-type Ca2þ 
channel blocker 
(negative inotrope) 
b-adrenergic receptor Epinephrine; b-adrener-
gic receptor agonist 
(positive inotrope) 
Propranolol; b-blocker 
(negative inotrope) 
Human ether-a-go-go Dofetilide; hERG chan-
related gene (hERG) nel blocker 
channel 
b-adrenergic receptors agonists 
are associated with a prolifera-
tive and angiogenic effect113 
b-blockers potentiate antiproli-
ferative and antiangiogenic 
effects in tumor and ECs114 
Undesirable blockade of hERG 
channel represents the most 
common form of drug-induced 
QT prolongation associated 
with risk of arrhythmias and 
possible sudden death115 
hERG channels are expressed in 
several tumor cells influencing 
their activity in cell survival and 
proliferation116,117 
Ib. Microvasculature validation. Example of representative drugs for vascular validation 
Vascular permeability Thrombin; permeabiliz- Vascular permeability is greatly 
ing agent increased in tumor vasculature 
VE-cadherin resulting in leaky and dysfunc-
disruption118 tional vessels119 
II. Physiologic validation of tumor tissue reduction 
IIa. Tumor tissue validation. Example of representative drugs used in traditional chemotherapy 
Target Approved drug Risk of direct cardiotoxicity/ Outcome of drug treatment 
bone marrow toxicity 
(reviewd previously 
by1,4,6,120,121,122) 
DNA intercalator Doxorubicin Recognized risk of cardiotoxicity 
(anthracycline) Myelosuppression. Recognized 
bone marrow injury 
Platinum analog Cisplatin, oxaliplatin Possible cardiotoxicity 
Myelosuppression and recog-
nized bone marrow injury 
Anti-metabolite 5-fluoruracil Possible cardiotoxicity associated 
with myocardial ischemia and 
arrhythmia 
Recognized bone marrow injury 
Mitotic disruptor Vincristine Low recognized cardiotoxicity 
(vinca alkaloid) Myelosuppression and recog-
nized bone marrow injury 
Typical cardiotoxicity type I 
associated with ROS gen-
eration and irreversible cell 
damage. 
Differently described behavior in 
2D vs. 3D-complex (Table 1) 
Differently described 
behavior in 2D vs. 
3D-complex (Table 1) 
Differently described 
behavior in 2D vs. 
3D-complex (Table 1) 
Possible cardioprotection by 
attenuation of doxorubicin-
induced cardiac myocyte 
toxicity123 
IIb. Tumor tissue validation. Example of representative drugs used in molecularly targeted chemotherapy 
Target Approved drug Risk of direct cardiotoxicity Outcome of drug treatment 
Growth factor receptors, Small molecule tyrosine 
intracellular signaling kinase and multiki-
pathways, possible nase inhibitors 
channel targets, and 
other cell functions 
HER2 Trastuzumab 
(monoclonal antibody) 
Cardiomyocyte survival, contrac-
tion dysfunction, or QT prolon-
gation 
Reviewed by Hedhli and Russell5, 
Force et al.124, and Raschi and 
De Ponti125 
Recognized risk of cardiotoxicity 
In general, possible different 
drug response in 2D vs. 3D 
complex due to the differen-
tially 3D activated or inhibited 
pathways compared with 2D 
Typical type II cardiotoxicity and 
‘on-target’effect126,127 
Differently described drug 
response in 2D vs. 3D-com-
plex (Table 1) 
(continued) 
Table 2 Continued 
Target Approved drug Outcome of drug treatment 
HER2 Lapanitib Low risk of cardiotoxicity No risk of cardiotoxicity as there 
is with the monoclonal anti-
body that targets the same 
receptor. 
Different signaling pathways are 
activated in cardiomyocytes 
by both strategies124 
EGFR Gefinitib Low risk of cardiotoxicity 
VEGFR, c-KIT, PDGFRa/ Sunitinib Recognized risk of cardiotoxicity Typical ‘off-target’ effect 
b, RET, CSF-1R, FLT3 PDGFR signaling important in 
(hERG) cardiomyocyte survival 
ATP depletion by mTOR 
increases activity in 
cardiomyocytes124 
RAF, VEGFR, c-KIT, Sorafenib Recognized risk of cardiotoxicity 
PDGFRa/b, FLT3 
BCL:ABL, PDGFRa/b, Imatinib Recognized risk of cardiotoxicity Strong warning for QT prolon-
c-KIT, (hERG) gation, risk of arrhythmia, and 
sudden death 
Possible hERG blockade by ABL 
inhibitors115 
mTOR Everolimus Warning risk of cardiotoxicity Warning for QT prolongation 
(lack of significant published Additional possible HIF-1 activ-
data) ity inhibition under hypoxic 
conditions (3D tumor 
environment)128 
Proteasome inhibitor Bortezomib Warning risk of cardiotoxicity Hypotension, warning for QT 
26 S prolongation. 
Additional HIF-1 transcription 
inhibition under hypoxic con-
ditions (3D tumor 
environment)129 
HDAC1, 2, 3, 6 Vorinostat Warning risk of cardiotoxicity Warning for QT prolongation 
Additional HIF-1 degradation 
induction under hypoxic 
conditions by HDAC inhibi-
tors (3D tumor 
environment)130 
III. Physiologic validation of EC proliferation and migration/angiogenesis 
IIIa. Angiogenesis validation. Example of representative drugs used in molecularly targeted chemotherapy 
Target Approved drug Risk of direct cardiotoxicity Outcome of drug treatment 
Growth factor receptors, Small molecule tyrosine Cardiomyocyte survival, contrac- In general, possible different 
intracellular signaling kinase and multiki- tion dysfunction or QT prolon- drug response in 2D vs. 3D 
pathways, and possi- nase inhibitors gation complex due to the differen-
ble channels targets Reviewed by Hedhli and Russell5 , tially 3D activated or inhibited 
Force et al.124, and Raschi and pathways compared with 2D 
De Ponti125 
VEGF Bevacizumab Warning risk of cardiotoxicity Disrupting VEGF signaling, most 
(growth factor) (monoclonal antibody) of these drugs exhibit pre-
dictable risk of hypertension 
and thrombosis (cardiovas-
cular indirect side effects) 
since VEGF does not just help 
new vessels grow, but also 
protects existing blood 
vessels131,132 
VEGFR, c-KIT, PDGFRa/ Sunitinib Recognized risk of cardiotoxicity 
b, RET, CSF-1R, 
FLT3, hERG 
VEGFR, EGFR, RET Vandetamib Warning risk of cardiotoxicity 
VEGFR, PDGFRa/b, c- Pazopanib Warning risk of cardiotoxicity 
KIT 
is particularly necessary for tissues with a diameter greater 
25–27 than 200 mm, as passive diffusional transport is ineffi-
cient. Thus, to replicate the complex 3D arrangement of 
cells and ECM, human microphysiological systems must 
include a vasculature made of perfused vessels that possess 
a physiologic flow. The molecular transport across the vas-
cular wall into normal tissues is largely driven by diffusion, 
but limited convection also takes place primarily in capil-
laries. Vascular permeability varies considerably among 
different tissues and is modulated by different factors 
such as blood flow.28 Vascular permeability undergoes sig-
nificant changes in pathological conditions such as wound 
healing, chronic inflammatory diseases, and cancer.25 
Unlike arteries and veins, capillaries consist of little more 
than a layer of endothelial cells (ECs) and connective tissue, 
along with a sparse covering of pericytes. They lack the 
smooth muscle cells that are present around the major ves-
sels, arteries, and veins. The ECs are embedded in a 3D 
microenvironment that mainly consists of a collagen-
based ECM and pericytes, and is influenced by biochemical 
(i.e. growth factors) and physical (i.e. shear stress) forces. 
Mimicking this complex microenvironment in vitro is a 
major challenge in vascular research. ECs are responsible 
for regulating a variety of functions including vascular tone, 
inflammation, coagulation, and sprouting of new vessels. In 
normal physiological conditions, vasculature is vasodila-
tory, antithrombotic, anti-inflammatory, and non-
angiogenic. These functions are controlled mainly by 
secreted factors from the EC.29 In this context, since ECs 
are mostly quiescent under physiological conditions, the 
development of new anticancer treatments is also directed 
toward targeting cell signaling pathways involved in patho-
logical EC proliferation and migration.5 By targeting endo-
thelium, the vascular supply to tumor tissue can be 
reduced, thereby inhibiting tumor growth. Antiangiogenic 
drugs are mostly targeted to the vascular endothelial 
growth factor (VEGF) signaling pathway. These drugs 
often have VEGF receptors (VEGFRs) as a common target. 
However, VEGF does not only help new vessels to grow, but 
it also protects existing blood vessels. Thus, due to disrup-
tion of VEGF signaling, many of these drugs are associated 
with a predictable risk of hypertension and coagulation that 
can lead to vascular dysfunction and thrombosis, 
respectively.4,7,30 
Tumor tissue 
Tumor cells have a remarkable ability to evolve in response 
to communication with the microenvironment. In this view, 
drug testing merely on isolated cancer cells is insufficient 
for a reliable estimation of drug efficacy in humans. The 
quest to develop improved models has progressed from 
2D cancer cell culture to 3D tumor spheroids made up of 
cancer cells and 3D tumor spheroids composed of a mixture 
of cancer and stromal cells.31–33 However, these models lack 
perfused vasculature and are limited in their ability to 
mimic the in vivo microenvironment critical for modeling 
drug delivery. Hence, we believe in vitro tumors with per-
fused capillaries, embedded in naturally occurring ECM, 
will produce improved drug screening studies. 
It is widely accepted that tumors actively communicate 
with vasculature to fulfill their growing metabolic 
demands, and in some cases to metastasize. Such commu-
nication brings several changes in vasculature, including 
angiogenesis mediated by VEGF, increased vascular leaki-
ness, and irregular vascular interconnections.25,34,35 In add-
ition, it is noted that lymphatic vasculature of tumors is 
generally dysfunctional.34,36,37 Together, these conditions 
are believed to increase the interstitial fluid pressure of 
tumors and consequently, increase the interstitial fluid 
flow from the tumor into surrounding tissue.34,38,39 As a 
result, in vivo tumors display uneven distribution of cyto-
kines, nutrition, and drugs across the tissue, posing a major 
challenge for efficient drug delivery.34,38–40 Therefore, to 
simulate a variety flow and pressure conditions, drug 
screening platforms need to have control over spatiotem-
poral resolution of interstitial flow and pressure in tumor-
on-chip devices. 
The inefficient vascular supply to tissues and increased 
growth rate create hypoxic conditions in certain regions of 
tumors. As a result, the microenvironment remains acidic, 
adversely affecting the action of many chemotherapeutic 
drugs as reviewed elsewhere.41,42 Hypoxia also promotes 
epithelial-to-mesenchymal transition, which is marked by 
increased motility of cancer cells and results into invasion of 
surrounding tissue.43 Further, hypoxia is believed to pro-
mote chemotherapeutic drug resistance in cancer cells by 
gene expression products such as P-glycoprotein.44 Hence, 
the in vitro tumors need to grow under hypoxic conditions 
closer to that experienced in vivo. We, and others, have pre-
viously developed a protocol for creating normal tissues 
that are perfused with dynamic vasculature under hypoxic 
and non-hypoxic conditions.45–47 
Interstitial flow and pressure, cellular behavior, drug dis-
tribution, and, in turn, drug efficacy are influenced by ECM, 
which constitutes a major part of the tumor tissue. Tumors 
are characterized by stiff ECM, which is typically composed 
of collagen, fibronectin, glycosaminoglycans, and proteo-
glycans.48,49 The active role of tumor ECM in cell signaling, 
as well as creating chemical and mechanical cues for cell 
migration, is reviewed elsewhere.48,50 Interestingly, it has 
been shown that it is possible to extract acellular ECM 
51,52 from in vivo tumors, and it is also possible to achieve 
collagen of varying stiffness by mixing it with other natur-
ally occurring ECM such as fibrin. We believe such strate-
gies could be implemented to create microphysiological 
tumor tissue. 
Apart from the constituents of the tumor microenviron-
ment discussed earlier, other major components are 
immune cells and tumor-associated fibroblasts.50,53,54 We 
and others have shown that fibroblasts secrete factors 
necessary for creating perfused vasculature,46,47,55 and, 
recognizing this fact, our current model of perfused net-
work includes fibroblasts.45,47 However, for the future 
advancement of the in vitro tumor model, appropriate 
tumor-associated fibroblasts may be needed. Among the 
immune cells, tumor-associated macrophages are perhaps 
the most significant cells as they affect a plethora of cancer 
processes, including angiogenesis, invasion, and metasta-
sis,50,53,56 and, importantly, they also adversely affect the 
chemotherapy.56 Hence, we believe that for future advance-
ment of microphysiological tumor tissue, it is important to 
integrate immune cells, particularly macrophages, on 
organ-on-chip platforms. 
Cardiac tissue 
Cardiotoxicity and altered cardiac function have been iden-
tified as significant side effects of anticancer drugs.4,57–60 At 
the cellular level, anticancer drugs can cause DNA damage, 
adenosine triphosphate (ATP) depletion, apoptotic protein 
release, reactive oxygen species (ROS) generation, electro-
lyte imbalance, lipid accumulation, and myocyte 
death.4,59–61 At the tissue level, these effects manifest as 
vasospasm, changes in force and frequency of contraction, 
and modified electrophysiology.4,59 As a result of these cell 
and tissue level effects, whole organ pathologies, such as 
left ventricular dysfunction, heart failure, myocardial ische-
mia, arrhythmias, and pericardial disease,4,57–60,62 are rea-
lized. These cardiac dysfunctions are often not discovered 
until clinical trials primarily due to limitations in current 
drug screening models. Similar to the previous discussion, 
cardiac animal models provide whole heart response to 
drugs, but many drugs have human specific effects. 
The key features of a microphysiological cardiac tissue 
system are as follows: (1) Use of a cardiac-specific matrix 
creates a 3D environment with the appropriate tissue-
specific architecture to induce the formation of tissue that 
better mimics in vivo physiology and pathology.63 (2) All 
cells are of human origin allowing assessment of human 
cell-specific drug responses. With further development of 
lineage-specific differentiation protocols, all cells implanted 
in the device may be derived from the same induced pluri-
potent stem cell line allowing for genetic homogeneity, and 
thus patient-specific responses, throughout the tissue com-
partments. (3) Tissues exhibit synchronous and rhythmic 
spontaneous contraction that allows detection of alterations 
in electrophysiological and contractile properties. Together, 
these properties represent the most critical parameters for a 
high-throughput cardiac tissue module for the screening of 
drug-induced cardiac side effects. 
Bone marrow 
Toxicity of pharmacological agents toward HSCs is a major 
problem for many therapeutic strategies, including cancer 
chemotherapy.64,65 Many antineoplastic drugs directly 
target the machinery of cell proliferation and thus also 
target HSC, which can be either quiescent, undergoing 
self-renewal, or differentiating into erythroid, myeloid, or 
lymphoid progenitors, or they may target more committed 
progenitors downstream of HSC.66 This results in immuno-
suppression, anemia, and thrombocytopenia, and many 
patients develop infections as a result. Blood transfusions 
can reverse anemia, and neutropenia can be addressed by 
treatment with granulocyte-colony stimulating factor 
(G-CSF). However, in severe cases of myelosuppression, 
patients have to undergo bone marrow transplantation – 
either restoration of autologous HSC removed before the 
start of chemotherapy or by allogeneic transplantation. 
Identifying new anticancer drugs that do not target HSC 
and their descendants is thus a priority. 
HSC reside in the bone marrow in a specialized niche 
composed primarily of ECM, osteoblasts, mesenchymal 
stem cells, and vascular ECs. A hematopoietic microphysio-
logical system will need to contain each of these cellular 
elements and the matrix will need to be extracted from 
bone marrow to ensure the presence of necessary extracel-
lular cues. It is essential that the system will model the fol-
lowing: (1) the maintenance of healthy HSCs that undergo 
renewal, (2) the generation of lymphoid lineage cells, (3) the 
generation of erythroid lineage cells, (4) the generation of 
myeloid lineage cells, and (5) the release of these cells into a 
circulatory system – the ‘blood.’ Incorporation of an 
immune compartment, specifically a hematopoietic com-
partment, into any platform of integrated microphysiologi-
cal systems will provide obvious advantages in anticancer 
drug-screening strategies. 
Platform design considerations 
Individual modules of microphysiological systems mimick-
ing critical organ functions can be developed separately 
and integrated to produce a platform for drug screening 
(Figure 1(a) and (b)). Such a platform should have the fol-
lowing features: biocompatible, flexible, high-throughput, 
reproducible design, easy fabrication, affordable, and a 
small footprint. 
Using soft lithography, it is possible to fabricate polydi-
methylsiloxane (PDMS) devices with micron range features 
reproducibly and precisely. In short, the process of fabrica-
tion involves the following: a master mold is created by 
photolithography on silicon wafers that are spin coated 
with SU8 and PDMS is poured on the master mold. 
Features of the mold are impressed on polymerized 
PDMS, which can be attached to another PDMS sheet or 
glass in a leakproof manner by using plasma treatment.45,47 
PDMS microdevices can be designed to create high-
throughput platforms and the designs can be easily altered 
to incorporate tissue-specific requirements, such as absorp-
tive interface for gut tissue. Further, PDMS devices are bio-
compatible, flexible, affordable, and our current designs can 
be adapted to create about 100 microtissues per 75 cm2 area. 
Moreover, by manipulating length and/or cross sectional 
area of microfluidic channels, it is also easy to maintain 
physiologic pressure drops across the tissue over time per-
iods exceeding 2 weeks.67 Importantly, PDMS is optically 
clear, offering a non-invasive system of real-time tissue ima-
ging with a high degree of spatial resolution. 
Our group has recently reported successful creation of 
perfused vascular networks in PDMS microdevices by 
allowing self-assembly and growth of endothelial colony 
forming cell derived-endothelial cells and stromal fibro-
ECM.45,68 blasts in a naturally occurring These tissues 
were formed in a PDMS device consisting of 0.1 mm2 
tissue chamber, which was fed with microfluidic channels 
on either side of the tissue chamber, which mimicked arter-
ial and venular supply to the tissue (Figure 1(a)). 
Significantly, the tissues were maintained in a medium 
without exogenous addition of VEGF or bFGF (primary 
growth factors for ECs and fibroblasts, respectively) and 
under physiologic oxygen concentration. These studies 
have shown that using microtechnology, it is possible to 
achieve an intricate balance of biochemical and mechanical 
cues, and cell–cell communication to generate anatomical 
features of inter-connected capillary networks. Importantly, 
once the microvascular network is developed and anasto-
mosed to the PDMS microfluidic channels, the tissue is fed 
only with the microvascular flow. This feature of the system 
is particularly important because it allows control over mor-
phogen delivery to tissues via the vasculature. Also, flow 
through the vasculature can be controlled by simply alter-
ing the hydrostatic pressure gradient.67–69 Thus, this tech-
nology has opened a plethora of opportunities for 
developing organ systems mimicking in vivo tissues for 
drug screening platforms. 
This technology can be extended to create vascularized 
tumor, cardiac, reproductive, and other major organ sys-
tems incorporating the cells of specific organs that mimic 
critical functions of the organ. An example of a microphy-
siological system module with appropriate 
instrumentation, such as a fluid pressure sensor, pump, 
and oxygenation system, is shown in Figure 1(a) and (b). 
To grow microtissues in a microdevice, organ-specific cells, 
ECs, and other stromal cells are initially mixed with ECM 
gels and the mixture is seeded in the microdevice (Figure 
1(a)). The microtissue is initially nourished by interstitial 
flow controlled by a pressure gradient across the microflui-
dic channels. Once the microtissue is vascularized, and the 
vasculature anastomoses with the high and low pressure 
microfluidic lines (Figure 1(a) and (b)), the tissue is com-
pletely nourished by the vasculature. 
To integrate prevascularized organ systems on an inte-
grated drug screening platform, the modules will be 
equipped with connector valves, which will allow modules 
to be daisy-chained for system-wide integration 
(Figure 1(a)). These modules can be connected so as to 
broadly mimic the human circulation in which the tissue 
chambers are connected by the circulation in parallel 
(Figure 1(b)). Important considerations for integration are 
compatible tissue culture media for all tissues on the plat-
form and relative scale of the tissues. Since most primary 
Figure 1 A prototype drug screening platform. (a) The microphysiological systems are developed in a central tissue chamber of individual modules. These micro-
tissues are initially nourished by interstitial flow and later by a perfused capillary network. The medium is pumped around a microfluidic network and is oxygenated 
through a bubble chamber. A pressure regulator controls ‘arterial’ pressure. Input and output channels on the arterial and venous side, respectively, allow mixing of 
fresh medium into the system. Individual tissue modules can be connected like jigsaw pieces, and connector valves allow ‘anastomosis’ of microfluidic channels. (b) 
Microfluidic channels are lined by EC and these anastomose with the microvessels in the tissue chamber to form a continuous vascular network linking all of the organs. 
(c) An example of how the major organs with a tumor might be placed such that their perfusion is in parallel to each other. (A color version of this figure is available in the 
online journal.) 
culture systems need a specialized medium for cell sur-
vival, differentiation, and growth, a universal medium sup-
plemented with organ-specific growth factors needs to be 
developed. Previously, it was shown that mixing two or 
more specialized growth media can be used to facilitate 
function and growth of cells in co-cultures.70–72 
To simulate the integrated function of various organs on 
the organ-on-chip platform, it is necessary to appropriately 
scale these systems, the strategies for which are recently 
reviewed.73,74 The scaling is critical because the vascular 
blood supply (determined as percent cardiac output of the 
blood supply) per unit mass of organ varies considerably 
among various organs, significantly differing the amount of 
drug received by the organs. For drug screening platforms, 
the appropriate scaling parameters are the blood supply per 
unit mass and relative mass of an organ system with respect 
to other organ systems. These are required to maintain simi-
larity with the in vivo organs. Notably, it may not be possible 
to maintain the relative mass of some of the organs, particu-
larly skeletal muscle and adipose tissue whose masses are 
greater than 500 times the mass of testis/ovaries.75 In such 
cases, the morphogen or concentrations on the arterial side 
of the flow of particular organ systems may be modified to 
accommodate the scaling parameter. 
The organ-on-chip platforms can be analyzed at molecu-
lar, cellular, tissue, and systemic level functional endpoints. 
The greatest advantage of the platform material is that it is 
optically clear and does not interfere with wavelengths of 
light required for fluorescence or bright field imaging. This 
feature allows non-invasive image-based measurement of 
parameters relevant to drug-induced endpoints of patho-
genesis, such as fluorescent lifetime imaging of metabolic 
state,76 assessment of calcium handling using calcium sen-
sitive proteins77 or calcium dyes,78 electrophysiology moni-
toring using voltage sensitive dyes,79 force–frequency 
response to pacing,80 perfusion, and vascular permeability. 
The organ-on-chip platform also allows easy collection of 
circulating media to analyze for soluble factors. 
Importantly, it is also possible to isolate each micro-organ 
for genomic or proteomic analysis as each microtissue is 
maintained in a separate tissue chamber. 
Incorporation of other organ systems 
Our device has been designed specifically to address the 
effects of anticancer drugs in vascular, tumor, cardiac, and 
bone marrow tissues. However, other organ systems have 
also demonstrated significant response to anticancer drugs 
and are important to consider as modules in future iter-
ations of the device. The general approach and method-
ology of our proposed modular platform is easily 
adaptable to other tissue systems. The gastrointestinal 
85,86 tract (GI),81,82 liver,83 kidneys,84 nervous system, skel-
etal muscle,87,88 and gonads89,90 have all been reported to 
have anticancer drug-related pathologies. 
Key features of developing a GI module include analogs 
of the small intestine (primary site of drug absorption) and 
the liver (primary site of drug metabolism). Small intestine 
tissue is comprised of a simple epithelium with absorptive 
cells and three different secretory lineages. Mimicry of this 
epithelium will require engineering of a similar epithelium 
to provide selective barrier function through which circu-
lating media can pass. This will filter drug compounds 
accordingly and secrete the appropriate factors into the 
tissue microenvironment. Liver tissue is complex and con-
sists of different zones with specific enzyme activity (phase 
I and phase II enzymes).91 A major factor that regulates the 
enzyme activity in these zones is oxygen tension (i.e. vari-
able distance from the closest blood vessel).92 To mimic liver 
function in a small microphysiological system compart-
ment, an oxygen gradient will need to be established 
within the compartment to achieve the differential phase I 
and phase II enzyme activity in hepatocytes. Directional 
flow across the oxygen gradient will be necessary to 
expose candidate drugs to the appropriate sequence of 
enzymes to ensure that drugs are metabolized as they are 
in vivo. 
Kidney compartments will need to mimic the main 
kidney functions of waste removal and metabolite excretion 
in the urine. Renal tubule epithelial cells are especially sus-
ceptible to toxic substances and are the critical cell that 
coordinates the secretion of waste products (including 
metabolized drug compounds) and the reabsorption of 
necessary nutrients.93 In vivo, both of these objectives are 
achieved by a counter-current mass exchanger. Thus, an 
engineered in vitro compartment could mimic this exchan-
ger using microfluidics and a selectively permeable mem-
brane, similar to that used in renal dialysis,94 coated with 
renal tubule epithelial cells. 
Nervous tissue modules will require blood–brain barrier 
(BBB) and blood–cerebrospinal fluid barrier analogs to 
simulate the specialized barrier properties that regulate 
access to microglia, neurons, oligodendrocytes, and astro-
cytes. Attempts at BBB reconstitution have been incomplete 
thus far, but the proper shear stress resulting from blood 
flow, as provided by our platform, is widely regarded as a 
key feature.95 
A skeletal muscle module will include contractile tissue 
and secretion of metabolically active factors into the vascu-
lar circuit. Appropriate secretion of metabolically active fac-
tors, such as interleukin-6, is necessary for hormonal 
communication and potential effects on drug metabolism.96 
In addition, the contractile tissue will require exogenous 
electrical stimulation since certain anticancer drugs affect 
neuromuscular activity.97 
Gonad compartments will require both a testis and an 
ovary model. Drug effects on the testis and ovary can be 
profound and can influence not only immediate reproduct-
ive output, but can also have long-term effects on gametes. 
The main components necessary to mimic are: (1) the main-
tenance of spermatogonial stem cells in the testis, (2) the 
development of ovarian follicles in the ovary, (3) recreation 
of the blood–testis barrier in males, and (4) secretion of the 
sex hormones testosterone and estrogen. 
Conclusion 
The need for improved methods of screening for anticancer 
drugs prior to clinical trials is apparent. We have developed 
a strategy to create a platform that incorporates 3D tissue 
modules from multiple organ systems to assess the efficacy, 
as well as the potential side effects, of anticancer drugs. 
These tissues are comprised entirely of human cells, are 
perfused by a microvasculature, and mimic the in vivo fea-
tures of vascular drug delivery and tissue response. The 
tissues are incorporated into a microfluidic device that 
allows control of multiple parameters that affect tissue 
physiology and drug response, as well as non-invasive 
monitoring of tissue state. The device is currently com-
prised of vascular, tumor, cardiac, and bone marrow tissues 
and is designed to allow for expansion of the system to 
include additional tissue modules. This in vitro approach 
represents a significant advance in the ability to identify 
potential adverse effects of anticancer treatment well 
before they reach clinical trials. 
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